Photosensitizer-9

Photosensitizer-9 是一种基于铱 (III) 的光敏剂,具有抗黑色素瘤活性,具备显著的光毒性 (IC50=0.98 μM) 与理想的光毒性指数 (PI=3.05),在光照下产生大量不依赖氧气的细胞内•OH,可在缺氧条件下介导光动力疗法,协同激活黑色素瘤细胞中的 PANoptosis (通过上调剪切型 Caspase-3、GSDMD-N、p-MLKL)、铁死亡 (ferroptosis) (通过破坏 GSH-GPX4-LPO 轴)、凋亡 (apoptosis)、焦亡 (pyroptosis)、坏死性凋亡,并在缺氧条件下通过促进损伤相关分子模式的释放诱导免疫原性细胞死亡,提高树突状细胞成熟率,还可降低荷黑色素瘤小鼠的肿瘤体积,可用于黑色素瘤的相关研究。
Photosensitizer-9
产品编号: MS-D76837 分子式: C50H34F6IrN6PS42+ 分子量: 1184.29
MolStrong 的所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务
规格 价格 是否有货 数量 购物车
50mg
询价
询价
100mg
询价
询价
250mg
询价
询价

产品描述

Photosensitizer-9 是一种基于铱 (III) 的光敏剂,具有抗黑色素瘤活性,具备显著的光毒性 (IC50=0.98 μM) 与理想的光毒性指数 (PI=3.05),在光照下产生大量不依赖氧气的细胞内•OH,可在缺氧条件下介导光动力疗法,协同激活黑色素瘤细胞中的 PANoptosis (通过上调剪切型 Caspase-3、GSDMD-N、p-MLKL)、铁死亡 (ferroptosis) (通过破坏 GSH-GPX4-LPO 轴)、凋亡 (apoptosis)、焦亡 (pyroptosis)、坏死性凋亡,并在缺氧条件下通过促进损伤相关分子模式的释放诱导免疫原性细胞死亡,提高树突状细胞成熟率,还可降低荷黑色素瘤小鼠的肿瘤体积,可用于黑色素瘤的相关研究。

生物实验数据

生物活性 Photosensitizer-9 is an iridium(III)-based photosensitizer with anti-melanoma activity that exhibits significant phototoxicity (IC50=0.98 μM) and a favorable phototoxicity index (PI=3.05), generates abundant oxygen-independent intracellular •OH upon light irradiation, and can mediate photodynamic therapy under hypoxic conditions by synergistically activating PANoptosis (via upregulation of cleaved Caspase-3, GSDMD-N, and p-MLKL), ferroptosis (via disruption of the GSH-GPX4-LPO axis), apoptosis, pyroptosis, and necroptosis in melanoma cells, while also inducing immunogenic cell death under hypoxic conditions by promoting the release of damage-associated molecular patterns and increasing dendritic cell maturation rate, and can reduce tumor volume in melanoma-bearing mice, making it useful for melanoma-related research.
体外研究
(In Vitro)

Photosensitizer-9 (Ir1) (500 nM; 24 h cell treatment, 3 min light exposure) 在光照下可于 B16-F10 细胞中产生大量不依赖氧气的细胞内•OH,在缺氧环境下,•OH 是驱动其光动力效应的主要 ROS 亚型。
Photosensitizer-9 (0.125-10 μM; 24 h post-light/dark incubation) 对 B16-F10 细胞表现出强效、不依赖氧气的光毒性,且暗毒性较低,其抗缺氧活性主要由•OH 的产生驱动。
Photosensitizer-9 (2 μM; 24 h cell treatment, 3 min light exposure) 可在缺氧条件下介导光动力疗法,协同激活 B16-F10 细胞中的 PANoptosis (通过上调剪切型 Caspase-3、GSDMD-N、p-MLKL)、铁死亡 (通过破坏 GSH-GPX4-LPO 轴)、凋亡、焦亡、坏死性凋亡。
Photosensitizer-9 (500 nM-2 μM; 24 h cell treatment/DC co-culture, 3 min light exposure) 可介导光动力疗法,在常氧和低氧条件下诱导 B16-F10 细胞发生免疫原性细胞死亡 (ICD)(ATP 释放、CRT 暴露、HSP70/HMGB1 分泌),进而在体外促进骨髓来源树突状细胞 (DC) 的成熟。

Cell Viability Assay

Cell Line: B16-F10 cells
Concentration: 0.125-10 μM (normoxia/hypoxia viability assay); 700 nM (normoxia scavenger assay); 2 μM (hypoxia scavenger assay)
Incubation Time: 24 h (post-light/dark incubation); 3 min (light exposure)
Result: Exhibited an IC50 of 0.54 μM and a phototoxic index (PI) of 13.48 under normoxia (light).
Reduced cell viability to 3% at 5 μM under normoxia (light) vs.
92% in dark.
Showed an IC50 of 0.98 μM and a phototoxic index (PI) of 3.06 under hypoxia (light).
Enabled restoration of cell viability from 8% to 43% under hypoxia when cells were treated with D-mannitol.

Immunofluorescence

Cell Line: B16-F10 cells
Concentration: 500 nM
Incubation Time: 24 h cell treatment, 3 min light exposure
Result: Produced a strong green dichlorofluorescein (DCF) fluorescence signal, but did not elicit a noticeable fluorescence signal in dark environments.
体内研究
(In Vivo)

Photosensitizer-9 (25 μM,50 μL;瘤内注射; 2 次 (day 0, day 4)) 可使小鼠黑色素瘤体积减少 89%,将肿瘤转化为热免疫原性表型,并激活系统性抗肿瘤免疫,且未观察到副作用。

Animal Model: C57BL/6 J (female, 6-8 weeks old, 18-23 g, subcutaneous injection of 5×105 B16-F10 melanoma cells)
Dosage: 25 μM,50 μL
Administration: intratumoral injection; 2 doses (day 0, day 4); followed by broad-spectrum white LED light irradiation at 50 mW/cm2 for 12 minutes with 1-minute pause every 3 minutes post-injection
Result: Achieved an 89% reduction in tumor volume.
Induced significant tumor cell destruction, reduced tumor cell density, and decreased proliferative capacity.
Increased splenic CD8+ T cells to ~18% and splenic CD4+ T cells to ~21% relative to control groups.
Increased tumor-infiltrating CD8+ and CD4+ T cells.
Elevated serum TNF-α to ~650 pg/mL and IFN-γ to ~28 pg/mL relative to control groups.
Converted immunosuppressed "cold" tumors to inflamed "hot" phenotypes.
Caused no significant body weight loss or histopathological lesions in vital organs.

化学信息

分子量 1184.29
分子式 C50H34F6IrN6PS42+

储存&溶解度

储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.

运输条件 Room temperature in continental US; may vary elsewhere.

Photosensitizer-9 相关分类

计算器

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子摩尔量 (g/mol)
Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)
起始浓度(M)× 起始体积(L)= 最终浓度(M)× 最终体积(L)
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
This equation is commonly abbreviated as: C1V1 = C2V2
溶液体积 = 质量 ÷ 配液浓度
Volume (to add to vial) = Mass (in vial) ÷ Desired Reconstitution Concentration
÷
分子量计算器
Enter the chemical formula of the compound to calculate its molar mass and elemental composition
g/mol

体内实验配液计算器

动物实验计算换算器

请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法:

比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL, 一共给药动物10只,您使用的配方为 10% DMSO + 40% PEG300 + 5% Tween 80 + 45% Saline / PBS / ddH2O, 那么您的工作液浓度为2 mg/mL。

母液配置方法:2 mg 药物溶于 100 μL DMSO ( 母液浓度为 20 mg/mL ), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。

体内配方的制备方法: 取 100 μL DMSO 母液, 添加 400 μL PEG300 混匀澄清, 再加 50 μL Tween 80, 混匀澄清, 再加 450 μL Saline / PBS / ddH2O 混匀澄清

以上为“体内实验配液计算器”的使用方法举例,并不是具体某个化合物的推荐配制方式,请根据您的实验动物和给药方式选择适当的溶解方案。

方案所需的各类助溶剂如: DMSO, PEG300, PEG400, Tween 80, SBE-β-CD, 玉米油等, 均可在MolStrong网站点击购买。

第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系客服为您提供正确的澄清溶液配方)
+
+
+

计算结果:

工作液浓度: mg/ml;

DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,

体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL Saline/PBS/ddH2O,混匀澄清。

1. 首先保证母液是澄清的;
           2. 一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。

开始您的科研之旅

20,0000+ 种高纯度分子化合物,专业靶点数据库,全程技术支持
让每一个实验数据都有坚实的分子基础